Table 1 Baseline characteristics of patients without (LNE-) or with (LNE+) mediastinal lymph node enlargement on CT scan of the chest. Data are expressed as counts (%) or mean with standard deviation. Reported p-values were obtained via t-test for independent samples or Pearsons’ Chi-squared test as applicable. BMI = body mass index; FVC = forced vital capacity; DLco = diffusion lung capacity for carbon monoxide; 6MWD = 6-min walk distance; COPD = chronic obstructive pulmonary disease; OSAS = obstructive sleep apnea syndrome; GERD = gastroesophageal reflux disease; GAP = gender age physiology.
N available observations | LNE- (n = 58) | LNE+ (n = 94) | p value | |
|---|---|---|---|---|
Age, years | 152 | 76 (7.3) | 74.7 (7.6) | 0.277 |
Sex | 0.627 | |||
Male | 152 | 45 (77.6) | 76 (80.9) | |
Female | 13(22.4) | 18 (19.1) | ||
Smoking history | 0.599 | |||
Current | 0 (0) | 1 (1.1) | ||
Former | 148 | 34 (60.7) | 60 (65.2) | |
Never smoker | 22 (39.3) | 31(33.7) | ||
BMI | 140 | 28.2 (3.9) | 27.31 (4.5) | 0.244 |
Use of oxygen therapy | 0.405 | |||
No | 137 | 51 (91.1) | 70 (86.4) | |
Yes | 5 (8.9) | 11(13.6) | ||
HRCT pattern | 0.504 | |||
UIP | 136 | 27 (52.9) | 43 (50.6) | |
Probable UIP | 14 (27.5) | 32 (37.6) | ||
Indeterminate for UIP | 7 (13.7) | 7 (8.2) | ||
Alternative diagnosis | 3 (5.9) | 3 (3.5) | ||
Anti-fibrotic treatment | 0.064 | |||
No treatment | 150 | 6 (10.5) | 9 (9.7) | |
Pirfenidone | 30 (52.6) | 32 (34.4) | ||
Nintedanib | 21 (36.8) | 52 (55.9) | ||
Follow up time (months) | 140 | 21.2(13.4) | 18.1 (12.4) | 0.166 |
FVC volume, L | 141 | 2.6 (0.7) | 2.56 (0.73) | 0.737 |
FVC % predicted | 152 | 85.6 (21) | 80.3 (19.5) | 0.118 |
DLco % pred | 142 | 58.9 (23.2) | 50.1 (21.7) | 0.023 |
SaO2% at rest | 142 | 94.4 (2.2) | 94.7 (2.7) | 0.563 |
Comorbidities | ||||
COPD | 152 | 4 (6.9) | 5 (5.3) | 0.732 |
Emphysema | 152 | 5 (8.6) | 13 (13.8) | 0.334 |
OSAS | 152 | 6 (10.3) | 8 (8.5) | 0.704 |
Chronic heart disease | 152 | 17 (29.3%) | 32 (34) | 0.544 |
Pulmonary hypertension | 152 | 2 (3.4) | 12 (12.8) | 0.054 |
GERD | 152 | 16 (27.6) | 30 (31.9) | 0.573 |
Anxiety/Depression | 152 | 2 (3.4) | 4 (4.3) | 0.804 |
Diabetes | 205 | 4 (6.9) | 24 (25.8) | 0.004 |
GAP Index | 0.038 | |||
Stage I | 148 | 25 (43.9) | 35 (38.5) | |
Stage II | 30 (52.6) | 40 (44.4) | ||
Stage III | 2 (3.5) | 16 (17.6) | ||
LNE number | ||||
1 | 32 (34) | |||
2 | 31 (33) | |||
≥ 3 | 31 (33) | |||
Larger LNE (mm) | 113 | – | 12.4 (2.4) | < 0.001 |